Novartis' New Kind of Pharma Deal

Novartis' two-step, $39 billion agreement to take a majority share of eye-group Alcon represents a very new kind of pharma deal: with pharma re-defined to include consumer care and surgery; and, for the first few years at least, with the buyer remaining an arm's length investor.

It's by far the biggest deal of this year; of last year's deals only AstraZeneca PLC's $15.6 billion acquisition of MedImmune LLC and Schering-Plough Corp.'s $14.4 billion Organon NV purchase out-flank it. [See Deal][See Deal] But Novartis AG's $11 billion agreement with Nestle SA to acquire a 25% stake in eye care firm Alcon Inc. is significant for reasons beyond its size. [See Deal]

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.